| Literature DB >> 16134930 |
Lara S Kallander1, Qing Lu, Wenfang Chen, Thaddeus Tomaszek, Guang Yang, David Tew, Thomas D Meek, Glenn A Hofmann, Christina K Schulz-Pritchard, Ward W Smith, Cheryl A Janson, M Dominic Ryan, Gui-Feng Zhang, Kyung O Johanson, Robert B Kirkpatrick, Thau F Ho, Paul W Fisher, Michael R Mattern, Randall K Johnson, Michael J Hansbury, James D Winkler, Keith W Ward, Daniel F Veber, Scott K Thompson.
Abstract
Inhibitors of human methionine aminopeptidase type 2 (hMetAP2) are of interest as potential treatments for cancer. A new class of small molecule reversible inhibitors of hMetAP2 was discovered and optimized, the 4-aryl-1,2,3-triazoles. Compound 24, a potent inhibitor of cobalt-activated hMetAP2, also inhibits human and mouse endothelial cell growth. Using a mouse matrigel model, this reversible hMetAP2 inhibitor was also shown to inhibit angiogenesis in vivo.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16134930 DOI： 10.1021/jm050408c
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446